This study was undertaken to determine whether a prolongation of pharmaceutical antithrombotic prophylaxis beyond hospitalization for hip fracture is associated with a reduced mortality rate. One hundred seventy-nine cases with hip fracture (patients older than 50 years of age) admitted to local general hospitals in 1999 who received postdischarge prescription of any antithrombotic agent (heparin, oral anticoagulants, antiplatelet drugs) and 179 ageand sex-matched patients with hip fracture who did not were included. Postdischarge mortality was assessed at 90 days. Compared
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Because antithrombotic treatment significantly reduces fatal PE in these patients (6) and reduces mortality for other thrombosis-related causes of death, we retrospectively evaluated the benefit of extending the anticoagulant treatment beyond the hospital period in patients with hip fracture.
MATERIAL AND METHODS
This study was carried out within the population of the health area n016 of the Veneto Region, Italy, which comprised 381,024 inhabitants in 1999. Patients more than 50 years old hospitalized in this area with a first diagnosis of hip fracture were identified through the specific disease code (820-821 of the International Classification of Diseases-ICD, ninth revision) on the population-based local health database.
Records for antithrombotic drugs (ATC-code=BO1) prescribed after hospital discharge and within 90 days thereafter were then analyzed using the patient's personal identification code. Each antithrombotic agent was then counted by means of the specific subcode as follows: B01AA = vitamin K antagonists; B01ABOl = unfractionated heparin (UHF); B01AB04-08 = lowmolecular-weight heparin (LMWH); BOlAC = antiplatelet agents.
Patients with a first episode of hip fracture who survived hospitalization were identified as cases when they had an antithrombotic drug prescribed within 90 days after the discharge from the hospital. Controls were selected among patients admitted to the hospital with the same disease but without any prescription of an antithrombotic drug in the 90 days after hospital discharge.
The case-control matching was performed as follows: from the general database of patients with a first episode of hip fracture, the relevant fields for matching were printed (age, gender, and use of antithrombotic drugs). Then a research assistant unaware of the clinical data identified the cases and selected the corresponding age-sex matched control.
Outcome of the study was death for all causes. Death was further classified by means of ICD-IX as thrombosis-related when caused by acute myocardial infarction, pulmonary embolism, and when death was generically attributed to cardiovascular causes. Other deaths due to underlying or other diseases or bleeding were considered not related to a thrombotic event. Records of hospital admission in the follow-up period were evaluated in all patients for the diagnosis of VTE.
Differences between groups were assessed by the Fisher exact test and odds ratio with 95% confidence intervals calculated using the approximation of Woolf. Survival curves were produced with Kaplan-Meier estimates.
RESULTS
From January 1999 to December 1999, a total of 407 patients over 50 years of age (0.26% of corresponding total population) were admitted to the hospitals of our health area with a first diagnosis of hip fracture.
Sixteen patients died during hospitalization. Of the remaining 391 patients, 179 patients (46%) were prescribed antithrombotic therapy in the 90 days following hospital discharge. The characteristics of these cases and of 179 age-and sex-matched patients in whom no antithrombotic therapy has been prescribed in the 3 months following discharge are reported in Table 1 . Most of cases and controls were elderly patients and the male/female ratio was 1:4. The duration of hospitalization was similar in the groups (15 days as a mean). Two cases had an episode of VTE (one deep vein thrombosis and one pulmonary embolism) during hospitalization. Most cases (72%) received subcutaneous heparin (unfractionated or low-molecular-weight or heparin followed by oral anticoagulants or in combination with antiplatelet therapy). The remaining patients were treated with oral anticoagulants (14%) or antiplatelet drugs (14%) as the sole antithrombotic treatment.
Overall, 26 deaths were recorded, five (2.8%) in identified cases and 21 (11.7%) in selected controls. Compared with controls, patients who received postdischarge prescription of antithrombotic agents had an odds ratio of 0.22 (95% confidence interval, 0.08-0.59) for allcause mortality (p=0.0011). Fig. 1 describes in detail the survival curves from hospital discharge (time 0) in both groups. Among the 26 deaths, 14 were classified as thrombosis-related deaths (two in the group of cases and 12 in the group of controls). Thrombosis-related deaths were significantly lower in the group of patients who Follow-up (days)
FIG. 1. Cumulative proportion of deaths in cases (patients in whom antithrombotic treatment after discharge was prescribed) and controls (patients in whom it was not prescribed).
were prescribed antithrombotic drugs (odds ratio=0.17, confidence interval 0.03-0.73, p=0.011). Among the remaining 12 patients, three died of bronchopneumonia, three for disseminated cancer, three as a consequence of cachexia and malnutrition, one for septicaemia. The two remaining patients died of cerebral bleeding, one in each group of cases and controls. VTE was recorded in only one case (nonfatal pulmonary embolism).
DISCUSSION
A high mortality rate ranging from 12% (7) to 41% (8) after 6 months complicates hip fracture surgery and one in five people will die in the first year (9) . A large autopsy-based study in a single district hospital (2) verified the causes of death in patients with hip fracture. Bronchopneumonia and cardiovascular complications were the prin-cipal causes of death, 37% of which were thrombosis-related deaths according to our definition. Pulmonary embolism peaked in the second week after injury and continued to be a significant cause of late mortality. The use of pharmacologic thromboprophylaxis significantly reduced fatal pulmonary embolism following hip fracture (6) .
The optimal duration of thromboprophylaxis is still a matter of debate and remains uncertain.
This prompted us to verify the out-of-hospital prescription of antithrombotic drugs, which, in accordance with a recent study (6) , was made in less than 50% of patients. This allowed us to arrange a case-control study in which a clear association between deaths from all causes and thrombosis-related death with the pharmaceutical prescription of antithrombotic drugs was clearly demonstrated. Recent trials that addressed the need for out-of-hospital LMWH prophylaxis in patients undergoing major orthopedic surgery of the lower limbs (10-14) support our findings. An apparent limitation of this study is that we isolated cases on the basis of postdischarge prescription of antithrombotic treatment. This procedure might have unbalanced the patient population but probably the risk of thromboembolic complications was higher in cases, which reinforces the results of the present study. On the other hand, the prescription of antithrombotic drugs might be related only to the preference of the physician at the time of discharge because the practice to treat patients is not uniform among physicians of our hospitals. In any case, this study strongly support the need to verify these results by mean of a randomized controlled clinical trial.
